S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:XLRN

Acceleron Pharma - XLRN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$178.75
$178.75
50-Day Range
$172.08
$179.68
52-Week Range
$108.82
$189.99
Volume
N/A
Average Volume
572,759 shs
Market Capitalization
$10.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$179.88

Acceleron Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.6% Upside
$179.88 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.36
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.95) to ($3.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.21 out of 5 stars

Medical Sector

1071st out of 1,098 stocks

Biological Products, Except Diagnostic Industry

173rd out of 174 stocks

XLRN stock logo

About Acceleron Pharma (NASDAQ:XLRN) Stock

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Receive XLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter.

XLRN Stock News Headlines

19 Charts to Calm Your Recession Fears
XLRN May 2022 140.000 put
Merck Closes Biggest Biotech Deal of the Year
Some Acceleron Investors Want a Better Deal From Merck
Acceleron Reports Third Quarter 2021 Financial Results
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
See More Headlines

Receive XLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter.

XLRN Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XLRN
Employees
312
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$179.88
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$179.00
Forecasted Upside/Downside
+0.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
9 Analysts

Profitability

Net Income
$-166,030,000.00
Net Margins
-226.01%
Pretax Margin
-225.99%

Debt

Sales & Book Value

Annual Sales
$92.52 million
Book Value
$11.74 per share

Miscellaneous

Free Float
60,116,000
Market Cap
$10.93 billion
Optionable
Optionable
Beta
0.13














XLRN Stock - Frequently Asked Questions

Should I buy or sell Acceleron Pharma stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last twelve months. There are currently 9 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" XLRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XLRN, but not buy additional shares or sell existing shares.
View XLRN analyst ratings
or view top-rated stocks.

What is Acceleron Pharma's stock price forecast for 2022?

9 Wall Street analysts have issued 1-year price objectives for Acceleron Pharma's stock. Their XLRN share price forecasts range from $179.00 to $180.00. On average, they anticipate the company's share price to reach $179.88 in the next year. This suggests a possible upside of 0.6% from the stock's current price.
View analysts price targets for XLRN
or view top-rated stocks among Wall Street analysts.

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.18. The biopharmaceutical company had revenue of $34.20 million for the quarter, compared to the consensus estimate of $35.39 million. Acceleron Pharma had a negative trailing twelve-month return on equity of 32.11% and a negative net margin of 226.01%. The firm's revenue for the quarter was up 51.6% on a year-over-year basis. During the same period last year, the firm posted ($0.66) earnings per share.

What is Habib Dable's approval rating as Acceleron Pharma's CEO?

11 employees have rated Acceleron Pharma Chief Executive Officer Habib Dable on Glassdoor.com. Habib Dable has an approval rating of 100% among the company's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN).

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $178.75.

How much money does Acceleron Pharma make?

Acceleron Pharma (NASDAQ:XLRN) has a market capitalization of $10.93 billion and generates $92.52 million in revenue each year. The biopharmaceutical company earns $-166,030,000.00 in net income (profit) each year or ($4.21) on an earnings per share basis.

How many employees does Acceleron Pharma have?

Acceleron Pharma employs 312 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.acceleronpharma.com. The biopharmaceutical company can be reached via phone at (617) 649-9200, via email at investor@acceleronpharma.com, or via fax at 617-649-9988.

This page (NASDAQ:XLRN) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.